Publikationen in Zusammenarbeit mit Forschern von Hospital Clinic Barcelona (50)

2023

  1. Metabolomics as a tool to predict the risk of decompensation or liver-related death in patients with compensated cirrhosis

    Hepatology (Baltimore, Md.), Vol. 77, Núm. 6, pp. 2052-2062

  2. Neuroblastoma RAS viral oncogene homolog (N-RAS) deficiency aggravates liver injury and fibrosis

    Cell death & disease, Vol. 14, Núm. 8, pp. 514

  3. Randomized, controlled clinical trial of the DIALIVE liver dialysis device versus standard of care in patients with acute-on- chronic liver failure

    Journal of Hepatology, Vol. 79, Núm. 1, pp. 79-92

2022

  1. Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH)

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 724-734

2021

  1. Abnormal liver function test in patients infected with coronavirus (Sars-cov-2): A retrospective single-center study from spain

    Journal of Clinical Medicine, Vol. 10, Núm. 5, pp. 1-18

  2. Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis

    Journal of Hepatology, Vol. 75, Núm. 3, pp. 589-599

  3. Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data

    Gastroenterology, Vol. 160, Núm. 1, pp. 193-205.e10

  4. Overview of virus and cancer relationships. Position paper

    Revista Espanola de Quimioterapia, Vol. 34, Núm. 6, pp. 525-555

  5. PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis

    Journal of Hepatology, Vol. 74, Núm. 5, pp. 1097-1108

  6. Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis

    JHEP Reports, Vol. 3, Núm. 6

2020

  1. Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS

    Journal of Hepatology, Vol. 73, Núm. 5, pp. 1082-1091

  2. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology

    Journal of Hepatology, Vol. 73, Núm. 4, pp. 842-854

2019

  1. Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH

    Gastroenterologia y Hepatologia, Vol. 42, Núm. 10, pp. 657-676

  2. An Accurate Data Preparation Approach for the Prediction of Mortality in ACLF Patients using the CANONIC Dataset

    Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society, EMBS

  3. An Accurate Data Preparation Approach for the Prediction of Mortality in ACLF Patients using the CANONIC Dataset

    2019 41ST ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY (EMBC)

  4. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial

    The Lancet, Vol. 393, Núm. 10181, pp. 1597-1608

2017

  1. Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study

    Transplant International, Vol. 30, Núm. 10, pp. 1041-1050

  2. Vascular diseases of the liver. Clinical Guidelines from the Catalan Society of Digestology and the Spanish Association for the Study of the Liver

    Gastroenterologia y Hepatologia

2016

  1. Development of hyperdynamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension

    Hepatology, Vol. 63, Núm. 1, pp. 197-206

2015

  1. Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy

    Clinical Gastroenterology and Hepatology, Vol. 13, Núm. 10, pp. 1846-1853.e1